TickerGuard
Buy Day today: Neutral (63) Broad market participation · major macro event coming up
CRVO

CervoMed Inc.

Healthcare · Biotechnology

1.60$ +0.6% vs. previous close Closing price · As of: Nov 4, 2026

Ownership

Ownership Structure

Who owns CervoMed Inc. (CRVO)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 63.5% of the shares are freely tradable; institutional investors hold 13.3%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 13.3%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 29.5%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 63.5%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 11.0%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 15Mio.

Largest Shareholders

Institutions

Institutions CRVO
Name Stake (%) Shares Change (%) Date
Woodline Partners LP 4.56 688,987 +0.0 06/30/2026
Vanguard Capital Management, LLC 2.09 316,202 +0.0 06/30/2026
Sabby Management LLC 1.65 248,880 +0.0 06/30/2026
Geode Capital Management, LLC 0.44 66,923 -10.0 06/30/2026
BlackRock Inc 0.36 53,845 +4.2 06/30/2026
Byrne Asset Management LLC 0.34 51,250 +248.6 06/30/2026
Citizens Financial Group Inc 0.25 37,477 +0.0 06/30/2026

Funds

Funds CRVO
Name Stake (%) Shares Change (%) Date
Vanguard MStar Total Stk Mkt Idx Invest 1.65 250,174 +0.0 09/30/2026
Fidelity Extended Market Index 0.48 72,670 -0.5 08/31/2026
Abante Quant Value FI 0.25 38,326 +0.0 08/31/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: November 4, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?